CRISPR Therapeutics AG short interest in 2026
In 2026, CRISPR Therapeutics AG's disclosed short interest ran from 22.81% of shares outstanding on 15 Jan 2026 to 19.72% on 15 Sep 2026, a change of -3.09 percentage points. The year's high was 28.30% on 15 May 2026 and its low 19.39% on 14 Aug 2026, averaging 22.53% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 16.54 days on 15 May 2026. Full history: CRISPR Therapeutics AG.
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 22.81% (15 Jan 2026)
- End of year
- 19.72% (15 Sep 2026)
- Change
- -3.09 pp
- High
- 28.30% (15 May 2026)
- Low
- 19.39% (14 Aug 2026)
- Average
- 22.53%
- Highest days to cover
- 16.54 (15 May 2026)
- SEC filings marked
- 6
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 22.81% | 11.92 | |
| 30 Jan 2026 | 22.97% | 12.10 | |
| 13 Feb 2026 | 23.59% | 13.21 | 10-K filed, results (8-K) |
| 27 Feb 2026 | 22.46% | 14.31 | |
| 13 Mar 2026 | 22.59% | 7.63 | |
| 31 Mar 2026 | 23.56% | 13.23 | |
| 15 Apr 2026 | 23.70% | 15.30 | |
| 30 Apr 2026 | 23.31% | 11.91 | |
| 15 May 2026 | 28.30% | 16.54 | 10-Q filed, results (8-K) |
| 29 May 2026 | 22.47% | 12.29 | |
| 15 Jun 2026 | 27.55% | 16.35 | |
| 30 Jun 2026 | 21.15% | 11.65 | |
| 15 Jul 2026 | 20.54% | 11.56 | |
| 31 Jul 2026 | 19.46% | 11.52 | |
| 14 Aug 2026 | 19.39% | 15.58 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 19.41% | 10.73 | |
| 15 Sep 2026 | 19.72% | 16.54 |
See also: CRISPR Therapeutics AG's full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.